+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genmab AS - logo

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.

Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 240 Pages
  • Global
From
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 1814 Pages
  • Global
From
Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 628 Pages
  • Global
From
Marginal Zone Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Marginal Zone Lymphoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 150 Pages
  • Global
From
Primary Mediastinal Large B-Cell Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Primary Mediastinal Large B-Cell Lymphoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 120 Pages
  • Global
From
Chronic lymphocytic leukemia - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic lymphocytic leukemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 210 Pages
  • Global
From
Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028 - Product Thumbnail Image

Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028

  • Report
  • October 2021
  • 78 Pages
  • Global
From
EPKINLY Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

EPKINLY Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • November 2023
  • 30 Pages
  • Global
From
Acute Lymphoblastic Leukemia Therapeutics Market Report and Forecast 2024-2032 - Product Thumbnail Image

Acute Lymphoblastic Leukemia Therapeutics Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 180 Pages
  • Global
From
Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions - Product Thumbnail Image

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

  • Report
  • November 2024
  • 716 Pages
  • Global
From
Central Nervous System Collaboration and Licensing Deals 2019-2024 - Product Thumbnail Image

Central Nervous System Collaboration and Licensing Deals 2019-2024

  • Report
  • October 2024
  • 500 Pages
  • Global
From
AI-Enabled Drug Discovery and Clinical Trials Market Report 2023-2033 - Product Thumbnail Image

AI-Enabled Drug Discovery and Clinical Trials Market Report 2023-2033

  • Report
  • June 2023
  • 267 Pages
  • Global
From
Global TCR Therapy Market, 2022-2035: Distribution by Target Indication, Target Antigen, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035 - Product Thumbnail Image

Global TCR Therapy Market, 2022-2035: Distribution by Target Indication, Target Antigen, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

  • Report
  • December 2022
  • 363 Pages
  • Global
From
Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035 - Product Thumbnail Image

Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Report
  • January 2023
  • 315 Pages
  • Global
From
Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 - Product Thumbnail Image

Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030

  • Report
  • April 2020
  • 536 Pages
  • Global
From
Richter's Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Richter's Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
T-cell lymphoma Market 2022-2026 - Product Thumbnail Image

T-cell lymphoma Market 2022-2026

  • Report
  • August 2022
  • 120 Pages
  • Global
From
Antibody Drug Conjugates Market Report 2022-2032 - Product Thumbnail Image

Antibody Drug Conjugates Market Report 2022-2032

  • Report
  • November 2022
  • 434 Pages
  • Global
From
Multiple Sclerosis (MS) Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2030 - Product Thumbnail Image

Multiple Sclerosis (MS) Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2030

  • Drug Pipelines
  • April 2023
  • 117 Pages
  • Global
From
Immunotherapy Drugs Market Size, Share & Trends by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Forecast to 2029 - Product Thumbnail Image

Immunotherapy Drugs Market Size, Share & Trends by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Forecast to 2029

  • Report
  • July 2024
  • 335 Pages
  • Global
From
Loading Indicator